The Point Of Care (PoC) Diagnostics Market is becoming increasingly important as healthcare providers seek timely test results near the patient rather than relying exclusively on centralized laboratories. According to Polaris Market Research, the global market was valued at USD 60.99 billion in the 2025 base year. It is projected to reach USD 66.50 billion in 2026 and USD 136.90 billion by 2034, representing a CAGR of 9.40% during the 2026–2034 forecast period. North America accounted for 42.60% of the global market in 2025. By product, infectious diseases accounted for 33.33% of revenue share, while the over-the-counter (OTC) segment is expected to grow at a CAGR of 9.9%. Key companies identified by Polaris Market Research include Abbott, BD, bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, QuidelOrtho Corporation, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc.

Why Near-Patient Testing Matters

PoC diagnostics are designed to deliver results at or near the point of care, supporting timely clinical decisions in settings such as clinics, hospitals, pharmacies, and homes. Rapid diagnostic testing can help care teams assess a patient without waiting for all testing to be completed in a central laboratory. This model is relevant to organizations aiming to streamline workflows and make diagnostic information available during a consultation.

The Polaris report covers a broad product landscape, including glucose testing, HbA1c testing, coagulation, fertility, infectious diseases, cardiac markers, thyroid-stimulating hormone, hematology, primary care systems, decentralized clinical chemistry, feces testing, lipid testing, cancer markers, blood gas and electrolytes, ambulatory chemistry, drug-abuse testing, and urinalysis.

Product Segments and Testing Needs

Infectious diseases represented 33.33% of market revenue share in 2025, according to the source page. This category includes testing associated with conditions such as HIV, hepatitis, influenza, respiratory syncytial virus, tuberculosis, and other infections. Infectious disease testing can support decisions about patient management and infection-control practices when timely results are needed.

Glucose testing is another product category in the report, alongside HbA1c testing and coagulation testing. Glucose testing supports monitoring needs in diabetes care, while HbA1c testing provides a different measure used in diabetes management. Other products address fertility, cardiac markers, thyroid function, blood chemistry, and urine analysis. For healthcare providers and diagnostic suppliers, product selection depends on the clinical question, sample workflow, operating environment, and how test results will inform care.

Read More @ https://www.polarismarketresearch.com/industry-analysis/point-of-care-poc-diagnostics-market

The report also includes decentralized clinical chemistry among its product categories. These systems extend selected chemistry testing beyond traditional central-laboratory workflows. Adoption decisions can involve workflow fit, staff training, quality procedures, connectivity, and the ability to integrate results into patient records.

Prescription Models and Regional Performance

The market is segmented by product, mode of prescription, end use, and region. Under mode of prescription, the report distinguishes OTC and prescription-based products. The OTC segment is expected to record the fastest growth, at a CAGR of 9.9% during the forecast period. Over-the-counter diagnostics can serve consumers seeking access to certain tests outside a conventional clinician-led testing pathway; the appropriate use of any test still depends on its intended purpose and instructions.

North America led the global market in 2025, accounting for 42.60%. The regional scope in the report also includes Europe, Asia Pacific, Latin America, and the Middle East & Africa. End-use settings include clinics, hospitals, home use, assisted-living healthcare facilities, and laboratories.

Competitive Landscape and Business Implications

The competitive landscape includes Abbott, BD, bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, QuidelOrtho Corporation, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc. These companies operate in a market where device performance, usability, test menus, quality systems, and distribution capabilities can influence product selection.

For B2B stakeholders, the projected expansion of the Point Of Care (PoC) Diagnostics Market highlights the importance of matching diagnostic solutions to clinical workflows and end-user needs. Healthcare systems can assess the balance between speed, test reliability, operational burden, and connectivity, while manufacturers can evaluate opportunities across infectious disease, glucose, and other testing categories. The source’s market figures offer a consistent starting point for business planning, with product and regional differences helping define more specific priorities.

More Trending Latest Reports By Polaris Market Research:

car-wash-services-market

us-hvac-systems-market

solid-state-vs-semi-solid-ev-batteries-who-is-actually-shipping

dimethyl-ether-market

peptide-synthesis-market

strategic-positioning-of-top-10-companies-in-the-endoscopy-market-in-2025

drone-detection-market

personal-cooling-device-market

directed-energy-weapons-market